Genovis AB publishes Annual Report 2024
Genovis’ Annual Report 2024 is as of today available at www.genovis.com
Contacts
Fredrik Olsson, CEO
Tel: +46 (0)70-276 46 56 fredrik.olsson@genovis.com
About Us
Headquartered in Kävlinge, Sweden, Genovis offers customers in the biopharmaceutical and research industries tools that facilitate and save time in the development of new treatment methods and diagnostics. Genovis enzyme products, known as SmartEnzymes, are used by scientists all over the world and the innovative product formats facilitate development and quality control of biological drugs. The Group consists of Genovis AB and the wholly owned subsidiary Genovis Inc. (US). Genovis shares are listed on Nasdaq First North Growth Market and Carnegie Investment Bank AB (publ) is the Company’s Certified Adviser, email: certifiedadviser@carnegie.se.
This is a translation of the Swedish original. In the event of any discrepancy between this translation and the Swedish original, the Swedish version shall prevail.
Attachments
Genovis Annual Report 2024